Home › Funds › Vestal Point Capital, LP › DYN

Vestal Point Capital, LP position in DYN

DYNE THERAPEUTICS INC · Health Care

Vestal Point Capital, LP reported holding 3,375,000 shares of DYN (DYNE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$75.0M, representing 1.75% of its reported portfolio and ranking #20 among its reported holdings. Vestal Point Capital, LP has disclosed DYN holdings in 7 of the last 9 reported quarters, going back to Q2 2024.

Latest position (Q2 2026)3.38M sh
Reported value held$74.96M
Portfolio Weight1.75%
First reportedQ2 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's DYN position evolved

Vestal Point Capital, LP first disclosed a stake in DYN in Q2 2024 at 225,000 shares (US$7.9M). The position peaked in Q2 2026 at 3,375,000 shares, worth US$75.0M. Across 7 filings, Vestal Point Capital, LP increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 3,375,000 shares valued at US$75.0M — a reduction of -625,000 shares quarter over quarter.. Notable position changes include a 281% increase in Q3 2025 (shares rose 55% over the following quarter), a 96% trim in Q4 2025 (shares fell 7% over the following quarter), a 3233% increase in Q1 2026 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 225.00K $7.94M New
Q1 2025 1.80M $18.83M New
Q2 2025 727.50K $6.93M Reduce
Q3 2025 2.77M $35.10M Add
Q4 2025 120.00K $2.35M Reduce
Q1 2026 4.00M $72.52M Add
Q2 2026 3.38M $74.96M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About DYN and 13F data

DYN (DYNE THERAPEUTICS INC) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding DYN

All DYN fund holders →

FAQ

How long has Vestal Point Capital, LP held DYN?

Vestal Point Capital, LP has disclosed DYN holdings in 7 of the last 9 reported quarters, going back to Q2 2024.

What is Vestal Point Capital, LP's current position in DYN?

As of Q2 2026, Vestal Point Capital, LP holds 3.38M shares of DYN (DYNE THERAPEUTICS INC), valued at $74.96M, representing 1.75% of its reported portfolio and ranking #20.

Has Vestal Point Capital, LP been buying or selling DYN?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP reduced its position in DYN. The position peaked in Q2 2026 at 3.38M shares.

Which other funds hold DYN?

Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.